EGFR and non-small cell lung carcinoma: EGFR-TKIs have long been the standard treatment for EGFRm+ NSCLC, and sequential 1G/2G EGFR-TKIs, followed by osimertinib, may provide better survival outcomes than frontline osimertinib [21].